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Abstract
Background: Nullomer peptides are the smallest sequences absent from databases of natural proteins. We first began
compiling a list of absent 5-amino acid strings in 2006 (1). We report here the effects of Nullomer-derived peptides 9R,
9S1R and 124R on the NCI-60 panel, derived from human cancers of 9 organs (kidney, ovary, skin melanoma, lung, brain,
lung, colon, prostate and the hematopoietic system), and four normal cell lines (endothelial HUVEC, skin fibroblasts BJ,
colon epithelial FHC and normal prostate RWPE-1).
Methods: NCI-60 cancer cell panel and four normal cell lines were cultured in vitro in RPMI1640 supplemented with 10%
Hyclone fetal bovine serum and exposed for 48 h to 5 μM, 25 μM and 50 μM of peptides 9R, 9S1R and 124R. Viability was
assessed by CCK-8 assay. For peptide ATP depletion effects, one cell line representing each organ in the NCI-60 panel,
and four normal cell lines were exposed to 50 μM of peptides 9R, 9S1R and 124R for 3 h. The ATP content was assessed
in whole cells, and their supernatants.
Results: Peptides 9S1R and 9R are respectively lethal to 95 and 81.6% of the 60 cancer cell lines tested. Control peptide
124R has no effect on the growth of these cells. Especially interesting the fact that peptides 9R and 9S1R are capable of
killing drug-resistant and hormone-resistant cell lines, and even cancer stem cells. Peptides 9R and 9S1R have a broader
activity spectrum than many cancer drugs in current use, can completely deplete cellular ATP within 3 h, and are less
toxic to 3 of the 4 normal cell lines tested than they are to several cancers.
Conclusions: Nullomer peptides 9R and 9S1R have a large broad lethal effect on cancer cell lines derived from nine
organs represented in the NCI-60 panel. This broad activity crosses many of the categorical divisions used in the general
classification of cancers: solid vs liquid cancers, drug sensitive vs drug resistant, hormone sensitive vs hormone resistant,
cytokine sensitive vs cytokine non sensitive, slow growing vs rapid growing, differentiated vs dedifferentiated cancers.
Furthermore peptides 9R and 9S1R are lethal to cancer stem cells and breast canrcinosarcoma.
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Background
Nullomers are the shortest string of monomers absent
from a species or species group. In 2007 Hampikian and
Andersen [1] published a list of Nullomers that were ab-
sent from all publicly available databases (called Primes);
for peptides there were 198 (5-amino acid strings) absent
from all known proteins. Nullomer DNA sequences have
been used to “watermark” DNA samples and prevent fo-
rensic contamination [2], and Nullomer-derived peptides
have been shown to be effective against prostate and
breast cancer cell lines [3]. In this study, we examined the
effects of 3 Nullomer-derived peptides on the NCI-60
panel of cancer cells, and 4 normal cell lines.
The current treatment of cancer cannot address many
aspects of human tumors driven by their cellular hetero-
geneity. For example, some cells in a tumor may be desig-
nated drug resistant [4] cancer cells, but other types of
cells, such as quiescent tumor cells and cancer stem cells
[5], are also out of reach of many of the current drug pro-
tocols. Due to these challenges, a new treatment paradigm
is emerging based on the targeting cancer cell metabolism,
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including aerobic glycolysis (Warburg effect). We report
here that two Nullomer-derived peptides (9R, 9S1R) have
a broad spectrum of activity against the NCI-60 panel,
and lead to dramatic cellular ATP depletion.
Methods
Cell lines
The NCI-60 panel of cancer cells was purchased from
Development Therapeutics of the NCI. Cells were
thawed in a water bath at 37 °C, and collected by centri-
fugation at room temperature. For maintenance, the cell
were grown in RPMI 1640 supplemented with 10%
Hyclone fetal bovine serum (FBS), and 1× penicillin
streptomycin (100× solution, Invitrogen) at 37 °C and
5% CO2. Passaging of cells was done at 80% confluence
after a PBS wash, cells were treated with Trypsin-EDTA
0.25% (Invitrogen).
Normal cell lines were purchased from the American
Type Culture Collection (ATCC, Manassas, VA). Human
endothelial cell line HUVEC (ATCC CRL-1730) was
grown in the ATCC formulated F-12 K medium with
0.1 mg/ml Heparin, 0.05 mg/ml endothelial cell growth
supplement and 10% FBS. Human skin fibroblast BJ
(ATCC CRL-2522) was grown in the ATCC formulated
Eagle’s Minimum Essential Medium supplemented with
10% FBS. Human prostate epithelial cell line RWPE-1
(ATCC CRL-11609) was grown in the Keratinocyte
Serum Free Medium (K-SFM, GIBCO) supplemented
with 0.05 mg/ml bovine pituitary extract (BPE) and
5 ng/ml human recombinant epidermal growth factor
(EGF). Human colon epithelial cell line FHC (ATCC
CRL-1831) was grown in the ATCC formulated DMEM-
F12 supplemented with 10 mM HEPES (final concentra-
tion 25 mM), 10 ng/ml cholera toxin, 0.005 mg/ml insu-
lin, 0.005 mg/ml transferrin, 100 ng/ml hydrocortisone
and 10% FBS. Only early cell passages were used for all
experiments. No human subjects (including human ma-
terial or human data) has been used in the research
reported in this manuscript. All cancer ell lines were ob-
tained from the NCI depository, and all normal cells
from the ATCC.
Reagents
Peptides 9R, 9S1R and 124R were made by Pierce Bio-
technology (Rockford, IL). HPLC purified peptides (pur-
ity >98%) were delivered in 0.5 mg/tube (lyophilized)
and stored at −20 °C. Peptides were solubilized in 1 M
Trehalose to produce 50 mM stock solutions. Only
freshly prepared solutions were used to treat cells. Tre-
halose final concentration in all reactions was 1 mM (a
dose without any effect on the growth of cancer and
normal cells). Sodium Azide (Sigma Aldrich) was solubi-
lized in water at 100 mM.
Screening the effect of peptides 9R, 9S1R and 124R on
the NCI-60 panel and normal cells
Three thousand–Five thousand normal or cancer cells/
well were seeded in 96-well plates. After 24 h incuba-
tion, peptides 9R, 9S1R and 124R were added to the
wells, with untreated cells as a control. After 48 h expos-
ure to 5 μM, 25 μM, or 50 μM peptides, cell viability
was quantified by the addition of 10 μl of cell counting
kit (CCK-8, Dojindo Japan) to each well, incubated for
4 h at 37 °C in a 5% CO2 incubator. After the 4 h incu-
bation, plates were monitored by a plate reader (Syner-
gyMx from BioTek, Winooski, VT) at an absorbance of
450 nm. Plate readings were exported to Microsoft Excel
and GraphPadPrism software. All the wells were ana-
lyzed in triplicates. The statistical analysis was done with
GraphPadPrism*. The survival index (SI) is the CCK-8
reading ratio of peptide-treated to untreated cells (minus
the blank values), multiplied by 100 to yield an index of
the percent surviving. A dose response using several
concentrations of the peptides (5 μM, 25 μM and
50 μM) was used for all cancer and normal cell lines.
The SI was used for screening in this study at the 50 μM
concentration of each peptide.
Measurement of cellular and cellular-supernatant ATP
content
Cancer cell lines (one cell line for each organ repre-
sented in the NCI-60 panel) and normal cell lines (3000-
5000/well) were seeded in 96 well microplates (white
plates from Nunc to block luminescence bleeding be-
tween the wells), and allowed to attach for 24 h. Then
cells were incubated for 3 h with peptides (50μΜ of 9R,
9S1R and 124R), or 100 mM sodium azide as a control.
After 3 h, 10 μl of a single reagent from Cell Titer
Glow™ (Promega) was added to cells. For the cellular
supernatant ATP content, the supernatant of each well
was transferred to a new microplate and 10 μl of a single
reagent from Cell Titer Glow™ (Promega) was added to
each supernatant. Complete reagent mixing in 96 wells
plates required gentle orbital shaking for 2–10 min. The
plate reading was taken by a SynergyMx plate reader.
Plate readings were exported to Microsoft Excel and
Graph-PadPrism software. All the wells were analyzed in
triplicates. The statistical analysis was done with the
GraphPadPRISM*.
Results
NCI-60 cancer cell lines’ sensitivity to peptides 9R, 9S1R
and 124R
In a previous work [3] peptide 9R (RRRRRNWMWC)
and its scrambled version 9S1R (RRRRRWCMNW) were
shown to be lethal to LnCap (prostate), MDA MB 231
(breast), B16 (mouse melanoma), and HUT 102 (Adult
T cell leukemia) cancer cell lines; while having more
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limited lethal effects on normal cell lines HMEC
(breast), PCS (prostate), WI-38 (fibroblast), and J774A.1
(mouse macrophages). Peptide 124R, a Nullomer-
derived control peptide (RRRRRWFMHW) had no effect
on any of the cells tested. In the present study, we ex-
tended the Nullomer anticancer investigation to the full
NCI-60 panel [6], which includes cancer cell lines derived
from a wide variety of human tumors originating from
nine organs. These tumors represent many types and
stages of cancer evolution in regard to both their meta-
static potential, and sensitivity or resistance to drugs.
The three peptides were prepared as previously pub-
lished: first solubilized in 1 M Trehalose and then di-
luted to three doses, 50 μM, 25 μM, and 5 μM final
concentration. Cells were incubated for 48 h, and then
their viability was assessed by CCK-8 assay [7]. Cell lines
were considered sensitive to peptides 9R, 9S1R and
124R if the survival index (SI) was less than 80%. This
means that for sensitive cell lines at least 20% of the cells
were killed by 50 μM peptide in a 48 h exposure.
As shown in [“Additional file 1: Results S1” and
“Additional file 2: Table S1” (A, B)] peptides 9R and
9S1R have broad activity against the NCI-60 panel: 95%
of the cancers are sensitive to peptide 9S1R, and 81.6%
are sensitive to peptide 9R; all of cell lines tested are re-
sistant to peptide 124R. Fifty seven cell lines are sensitive
to 50μΜ of 9S1R, with a SI between 3.80% (MALME-
3 M) and 71.20% (MOLT-4). Notably, nine cell lines
have a SI of less than 10%: kidney UO-31 and ACHN,
prostate DU-145, ovarian OVCAR-8 and OVCAR-4,
colon COLO 205, melanoma UACC-257 and SK-MEL-5
and MALME-3 M, and breast HS-578 T. Only three cell
lines (5%) are resistant to peptide 9S1R: colon cancer
HT-29 and HCC 2998, and lung cancer A-549 ATCC.
Forty-nine of the NCI-60 cancer lines are sensitive to
peptide 9R with a SI between 4.10% (MALME-3 M) and
78.10% (IGR-OV1). Four cell lines have a SI of less than
10% after exposure to 9R: melanoma SK-MEL-5 and
MALME-3 M, breast HS-578 T, and lung EKVX. Eleven
cell lines (18.3%) are resistant to peptide 9R: kidney
A498 and UO-31; prostate PC-3; ovarian SK-OV-3;
colon HT-29; melanoma SK-MEL-28; breast MCF-7; lung
NCI-H226, NCH-H522, A549 ATCC and NCI-H322M.
All told, peptide 9R and 9S1R are lethal to cancer cells
from all nine organs represented in the NCI-60 panel.
We have classified each cell line according to the four
possible combinations of Nullomer sensitivity response
[“Additional file 2: Table S1” (C)]. Eighty percent of the
NCI-60 cancer cell lines are sensitive to both peptides
9R and 9S1R (category I). For example, all the leukemic
and CNS cell lines are sensitive to both peptides 9R and
9S1R and thus belong to category I. At the opposite end
of the spectrum, two cell lines are resistant to both pep-
tides 9R and 9S1R (category IV): colon HT-29 and lung
A549 ATCC. Fifteen percent of the NCI-60 lines are
sensitive to 9S1R, but resistant to 9R (category II). Only
one cell line, colon HCC 2998, is sensitive to 9R but re-
sistant to 9S1R (category III). Since peptides 9R and
9S1R are scrambled versions of each other, the difference
in sensitivities indicates that they likely have different
targets within the cell.
It is notable that both peptides 9R and 9S1R kill prostate
cancers that are androgen independent (PC-3 and DU-145),
and those that are androgen dependent for their growth
(LnCap) [3]. Furthermore, peptides 9R and 9S1R kill breast
cancer cell lines that are hormone independent and triple
negative (MDA-MB-231, BT-549, HS-578 T, and MDA-
MB-468), as well as those that are hormone dependent
(MCF-7 and T-47D). The killing effect of peptides 9R and
9S1R is not limited to any particular range of doubling time
(DT) [(http://dtp.nci.nih.gov/docs/misc/common_files/
cell_list.html), “Additional file 2: Table S1”, (A)]. Cells
with low DT like colon HCT-116 (17.4 h) and K-562
(19.6 h), as well as those with high DT like lung
HOP-92 (79.5 h) and CNS SNB-75 (62.8 h), are all
killed by peptides 9R and 9S1R. Since our screening
was limited to 48 h peptide exposure, cell lines with
high DT didn’t have time to complete a full cell cycle. This
implies that the targets for peptides 9R and 9S1R are not
involved in DNA replication or mitosis.
We have compared the activity spectrum of peptides 9R
and 9S1R with ten classes of anticancer drugs approved by
the FDA for patients ([8], “Additional file 3: Table S2”),
most of which are used in combination. There is no single
anticancer drug that matches the broad activity spectrum
of peptides 9R and 9S1R against cancers from nine organs,
including solid tumors (like prostate, breast, CNS and
lung cancers), as well as liquid tumors (leukemia, lymph-
oma). Although many classes of anticancer drugs target
DNA replication or microtubules, these drugs do not have
the same broad spectrum of activity as 9R and 9S1R. We
note that CNS, kidney, colon and melanoma cancers have
fewer available drug treatment options, compared to
leukemia, ovarian and breast cancers–but peptides 9R and
9S1R are active against all of these.
Sensitivity of normal cells to peptides 9R, 9S1R and 124R
in viability assays
Normal cells from four organs: skin fibroblasts BJ,
endothelium HUVEC, colon epithelium FHC, and
prostate RWPE-1 cell lines were also treated with
9R and 9S1R [“Additional file 4: Results S2” and
“Additional file 2: Table S1”, D)]. At 25 μM, 9R has
no effect on HUVEC or BJ normal cell lines; and
the effect on the constantly-renewing intestinal cell
line (FHC) was below our sensitivity threshold of
20% lethality (the cells were 90% viable). Of the
non-cancer cells tested, RWPE-1 prostate cells
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showed the greatest sensitivity to 9R, dropping just
below our sensitivity threshold of 20%, (the cells
were 79% viable). However, at this dose many cancer
cell lines in our screen suffer far greater lethality.
For example, treatment with 25 μM 9R decreases
viability of several cancers by over 50%: M14 melanoma,
EKVX lung cancer, HCC 2998 colon cancer, SR and CCRF
leukemia cell lines. Future studies will determine the most
effective doses for each peptide against each particular can-
cer cell line.
Sensitivity of normal cells to 9S1R was greater than
that of 9R, however two of the four normal cell lines
tested showed no effect on viability at 25 μM 9S1R
(HUVEC and BJ). FHC cells treated with 25 μM 9S1R
had 26% reduced viability (74% survived), and RWPE-
1 cells’ viability was reduced by 79% (21% survived).
The present study is principally a screening assess-
ment of 9R and 9S1R with results shown for three
doses (50 μM, 25 μM and 5 μM). We have analyzed
and classified the results for all 64 cell lines based on
reaction to the highest dose (50 μM), however, we ex-
pect that modifications to these peptides will allow
for lower clinical doses. The differential response of
various cancer lines, and the relative resistance of
some normal cell lines, points to both the promise
and challenges for translation of these Nullomer pep-
tide drugs to the clinical setting. The promise of
these peptides is perhaps best illustrated by the fact
that doses of 25 μM 9R are effective against several
cancer cell lines (see Additional file 1: Result S1), but
have little or no effect on normal cells.
Peptides 9R and 9S1R ATP depletion effect on cancer
cells
We examined the cellular ATP content for one line from
each organ represented in the NCI-60 panel: SN12C,
DU-145, IGR-OV 1, K-562, COLO 205, MALM-3 M,
HS-578 T, U251 and EKVX. Cellular ATP content was
evaluated after 3 h exposure to 50μΜ of peptides 9R,
9S1R and 124R. In just 3 h, 9S1R reduced the cellular
ATP content of all nine cell lines by more than 90%,
resulting in ATP levels that were a small fraction of the
untreated cells: from 0.59% (MALM-3 M) to 6.65%
(COLO 205) [Fig. 1 (a, b), “Additional file 5: Table S3”].
The ATP depletion effect of peptide 9R is also substan-
tial, reducing ATP to between 9.87% (MALM-3 M) and
58.56% (COLO 205) of the untreated cells. This differ-
ence between the ATP depletion effect of peptides 9R
and 9S1R may be due to the differential expression of
different cellular targets in these cells. For comparison,
we also treated each cell line with 100 mM sodium
azide, a selective inhibitor of complex IV in the mito-
chondrial respiratory chain. In many cases, the two
peptides had a greater ATP depletion effect (measured
after 3 h) than the 100 mM sodium azide.
Peptides 9R and 9S1R ATP depletion effect on normal
cells
Normal cell lines (HUVEC, BJ, FHC and RWPE-1) were
tested in the same way as the cancer cells. At 50 μM
peptide 9S1R completely depleted the cellular ATP con-
tent of HUVEC and RWPE-1 cells; however, its effect on
BJ and FHC cells was moderate. In fact, while 9S1R re-
duced cellular ATP in all the cancer lines below 7% of
the untreated cells, ATP in 2 of 4 normal cell lines was
39% of the untreated (BJ), and 54% (FHC) of the un-
treated. We note that depletion of ATP was not directly
related to loss of vitality for all cell lines. This differential
response to 9S1R-even at high dosage-suggests that this
peptide may be useful to treat specific tumors.
Peptide 9R completely depleted the ATP content of
RWPE-1, but had no effect on the three other normal cell
lines. Peptide 124R produced no ATP depletion effect on
normal cells [Fig. 1 (c), “Additional file 5: Table S3”], and
served as an effective control Nullomer-derived peptide
treatment.
Peptides 9R, 9S1R and 124R effects on ATP levels in
cellular supernatants
F0F1-ATP Synthase is normally expressed by the internal
membrane of the mitochondria, but many cancer cells ex-
press it on the cell surface where it secretes ATP into the
cell supernatant [9]. In order to explore ATP production
in greater detail, we treated cancer cells with the three
peptides, and determined the ATP content in the superna-
tants after 3 h’s incubation. As shown in Fig. 1 (d), pep-
tides 9R and 9S1R deplete the ATP secreted by K-562 and
COLO 205 cells into the culture supernatant. While the
significance of this effect needs further exploration, one
possible target of the Nullomer-derived peptides may be
Ectopic F0F1-ATP Synthase.
Discussion
Peptides 9R and 9S1R are COMPARE-negative drugs: Af-
fecting a great variety of cancer cell types
To our knowledge, this is the first study of the antican-
cer effects of synthetic small peptides on the NCI-60
panel. The website http://crdd.osdd.net/raghava/can-
cerppd/ [10] reviews 3491 anticancer peptides (ACP),
but none have been tested against the full NCI-60 cancer
cell panel in a single study. Since its introduction in
1990 the “NCI-60 screen” [6] failed to identify any single
drug with broad activity against cancer types. Although
there are specific markers for many cancers, the uncon-
trolled growth of tumors is the most obvious trait shared
by all of them, along with local invasion and distant me-
tastasis. One might think that any drug capable of
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inhibiting DNA replication or the mitotic apparatus
would be effective against many types of cancers. How-
ever, the anticancer drugs approved by the FDA, de-
scribed in “Cancer: Principles & Practice of Oncology”
[8], do not include a single drug used in the treatment
of all nine tissue types represented in the NCI-60 panel.
This is also true for all the drugs tested against the larger
cancer cell line panels, for example the cancer cell line
encyclopedia (CCLE), which includes 1036 cell lines
[11], and the cancer genome project (CGP) with 727 cell
lines [12]. Each approved anticancer drug has a tumor-
type selectivity or “fingerprint” that can be analyzed
using the “COMPARE algorithm” [13]. Since peptides 9R
and 9S1R are active against cancers from all nine organs
represented in the NCI-60 panel, they can be considered
“COMPARE-negative drugs” and this makes them differ-
ent from other tested drugs.
It is remarkable that cancer cells from all nine NCI-60
organs (kidney, prostate, ovary, hematopoietic system,
skin, CNS, colon, and lung) are sensitive to 9R and 9S1R
peptides. These nine organs differ widely in their func-
tions, metabolism, and reproductive rates. The skin and
the hematopoietic system constitutively renew, while the
ovary and the brain are nearly quiescent. Of course all of
a
b
c
d
Fig. 1 ATP depletion of cancer and normal cell lines by Peptides 9R, 9S1R, 124R and sodium azide. 50 μM of peptides 9R, 9S1R and 124R (3 h
incubation) effects on cellular ATP content of cancer and normal cell lines. a: MALME3M, COLO205, IGR-OV1, SN12C and DU-145; b: U251, EKVX,
HS-578 T and K-562; c: HUVEC, BJ, RWPE-1 and FHC; d: Supernatant ATP content of cancer cells COLO205, K-562 and DU-145. Controls: untreated
cells, 100 mM Sodium Azide, EW (empty wells). All wells in triplicates. Each panel is a representative of three experiments
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the cancer lines share some basic physiological mecha-
nisms like the production of ATP by glycolysis and/or
oxidative phosphorylation. Peptide 9R and 9S1R’s broad
spectrum of activity can be explained by some common
feature of all types of tissues represented in the NCI-60
panel–a feature that we expect will be found in what is
called “cells of origin of cancer” [14]. Peptide 9R and
9S1R defy many of the commonly used classification sys-
tems for cancer drug types, and further studies are needed
to more fully characterize and classify these drugs.
Histology types affected by Nullomer-derived peptides 9R
and 9S1R
The NCI-60 panel includes a wide array of histological
types (http://discover.nci.nih.gov/cellminer/celllineMetada-
ta.do). We show that peptide 9R and 9S1R sensitivity is not
restricted to any particular histological type in the panel.
This is important since cancer generally evolves from his-
tologically distinct and differentiated cells, to an undiffer-
entiated state that is characterized by local and distant
metastasis with accompanying drug resistance. Peptides 9R
and 9S1R are effective against undifferentiated glioblast-
omas (SF-268, SF-295, SF-539, U251); undifferentiated
lung cancers (HOP-62, HOP-92, NCI-H460); poorly differ-
entiated ovarian cancer (IGR-OV1), moderately differenti-
ated ovarian cancers (OVCAR-3, OVCAR-4) and well
differentiated ovarian cancer (OVCAR-5); poorly differenti-
ated kidney cancers (SN-12C, RXF 393); amelanotic mel-
anoma (LOX IMVI) and melanotic melanoma (SK-ML-2,
M14, UACC-62, UACC-257). In addition, peptides 9R and
9S1R are effective against adenocarcinomas (cancers of
glandular tissues) like colon HCC-2998 and breast MCF-7,
carcinomas (cancers from epithelial tissues) like lung NCI-
H226, and blastomas (cancers from embryonic tissue of or-
gans) like CNS SF-268. Furthermore, the breast cancer cell
line HS578T is sensitive to both peptides 9R and 9S1R.
This type of breast cancer, which constitutes 1% of all
breast cancers, is a complex combination of epithelial and
mesenchymal metaplasic carcinoma (carcinosarcoma) [15].
Such cancers are far more aggressive and have a poorer
prognosis than even triple negative breast cancers.
Peptide 9R and 9S1R effects on solid vs liquid tumors
The treatment of solid and liquid cancers in patients is
quite different from cell culture conditions. However,
one can assess the effects of novel drugs on tumors iso-
lated from both solid and liquid tissues in culture. Can-
cers of the ovary, CNS, lung, kidney, melanoma,
prostate, colon and breast are considered solid tumors.
Leukemia and myeloma are considered liquid cancers.
Normally cancer drug effects are limited to solid or
leukemic cancers [8]. For example, taxol and its deriva-
tives are not effective against leukemia, and the prote-
asome inhibitor Velcade has been used effectively only
against myeloma. In general, leukemia has a better prog-
nosis than solid tumors.
As shown in “Additional file 3: Table S2” there are 29
drugs currently used against leukemia, 17 drugs against
breast cancers, 7 drugs against melanoma, 8 drugs
against kidney cancers, and only 5 drugs against CNS
cancers. Peptides 9R and 9S1R are effective against all of
these cancer cells lines (both solid and liquid cancers)
(“Additional file 2: Table S1”), including the aggressive ATL
leukemia (HUT102) [3]. Therefore the target (s) of peptides
9R and 9S1R are expressed by solid and liquid tumors.
The doubling time (DT) of the NCI-60 cancer cell lines
panel
The diversity of cancer cell line DTs has practical impli-
cations for cancer research. It is difficult to standardize
all the parameters of in vitro cell growth (cell density,
degree of confluency, volume of culture medium, types
of 96-1536 wells microplates, and the exposure time to
drugs), especially when using large panels of cell lines
that have varying DTs. Because of this, the literature is
replete with varying screening protocols. For example,
the NCI 48-h incubation protocol for the NCI-60 screen
uses a scale of inoculation densities to accommodate
various DTs (5000–40,000 cells per well in a 96 well mi-
croplate) [6]. For a panel of 639 cancer cell lines Garnett
et al. [10] used cell densities of 70% confluency in 96
and 384 wells microplates, with a 72 h exposure to
drugs. With the availability of automated platforms, Gri-
ner et al. [16] used 1000 cells/5 μl in a 1536 well plate,
and a 48 h exposure to drugs. In our screening method,
we used 5000 cells/100 μl in 96 wells plate and an ex-
posure time of 48 h. These differences in research proto-
cols make it difficult to compare results across studies.
Nevertheless, we have shown that Nullomer-derived
peptides 9R and 9S1R are effective against cancer cell
lines with short (~24 h) and long (62-79.5 h) DTs. For
example, the peptides were effective against kidney can-
cer lines 786.0 (22.4 h DT) and RFX 393 (62.9 h DT);
CNS cancers U251 (23.8 h) and SNB-75 (62.8 h), lung
cancers NCI-H460 (17.8 h) and HOP 92 (79.5 h). Since
we used a treatment period less than the DT of many
NCI-60 cells, and the peptides were effective against cells
having a broad range of DTs, peptides 9R and 9S1R do not
appear to target DNA replication or the mitotic apparatus.
Peptides 9R and 9S1R kill resistant and non-resistant
cancer cells
In the context of this study, cancer cell resistance is in
fact four distinct phenomena: resistance to drugs, hor-
mone and cytokine resistance, resistance of cancer stem
cells, and peptide resistance. It would be misleading to
put them all in the same category [17], and we separate
them here.
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Drug resistance
Resistance starts with one drug, but often evolves to
what is called multidrug resistance (MDR), usually medi-
ated by the ABC transporter family. A review by Szakacs
et al. [18] shows that among 22 clinical trials (two of
which are not yet finished), 15 of 20 drugs deliver “no
benefit” to patients due to secondary resistance. In that
review, he proposes that, “drug resistance can be re-
versed by hydrophobic peptides”. In keeping with that
suggestion, we have tested the Nullomer-derived pep-
tides against all 60 lines in the NCI-60 panel. In our
preparation for this study, we found that identifying
which cell lines are “drug resistant” among the NCI-60
panel is not a trivial matter of literature search. In fact,
we have found much contradictory information in differ-
ent published works–just as Baggerly et al. documented
in their seminal study [19]. We finally based our own
evaluation criteria for drug resistance on the work by
Yadav et al. [20], in which they investigated the sensitiv-
ity of the NCI-60 panel to 1400 drugs, and established a
list of drug resistant and drug sensitive cell lines. From
the Yadav et al. list of drug resistant cell lines we found
several that are sensitive to peptide 9S1R: NCI/ADR-
RES, SK-OV-3, OVCAR-5, HS-578 T, MDA-MB-231,
SNB-19, EKCX, NCI-H460, HOP 62, NCI-H322M. Of
the Yadav classified drug resistant lines that are sensitive
to 9S1R, with the exception SK-OV-3 and NCI-H322M,
all are also sensitive to 9R.
Hormone and cytokine resistance
Breast, prostate and ovarian cancers have a hormone de-
pendency phase. In this way, the hormone resistance
phenotype is different from MDR. Peptide 9R and 9S1R kill
both hormone sensitive and hormone resistant cancers. For
example, both peptides kill hormone sensitive prostate can-
cers such as LnCap [3], and hormone resistant prostate can-
cers like PC-3 and DU-145 (“Additional file 2: Table S1”).
For breast cancer, peptide 9S1R kills hormone resistant
breast cancers (MDA-MB-231, BT-549, HS 578 T and
MDA-MB-468), and hormone sensitive breast cancers
(MCF-7 and T-47D) (“Additional file 2: Table S1”). Peptide
9R kills all the same lines with the exception of the MCF-7
cell line (“Additional file 2: Table S1”). Cytokines, like inter-
leukin 2, are growth factors necessary for the survival and
growth of many immune cells. Both peptides 9R and 9S1R
kill both interleukin 2-dependent leukemia MOLT-4 ([21],
Suppl. “Additional file 2: Table S1”), and the interleukin 2-
independent HUT 102 [3].
Cancer stem cells resistance
Cancer stem cells play an important role in cancer
relapse, whether the stem cells have their origin in the
initial tumor, or are induced by chemotherapy. They
have been described in solid tumors and hematopoietic
malignancies. These cells are characterized by their re-
sistance to drugs [22] and radiation. Both peptides 9R
and 9S1R kill cancer stem cells like Ovarian OVCAR-3
[23], lung cancer NCI-H460 [24], and colon cancer
HCT116 ([25], “Additional file 2: Table S1”).
Peptide resistance
Resistance to peptides is a new phenomenon in the lit-
erature because peptides have been considered “resist-
ance free” [26]. We have found resistance to our peptide
drugs to be cell line specific. Cancer cell line A549
ATCC is drug resistant in the Yadav et al. list [20], and is
resistant to both peptides 9R and 9S1R. Two other cell
lines (NCI-H322M and SK-OV-3) are resistant to drugs
in the Yadav et al. list [20], and are resistant to peptide
9R–but they are sensitive to 9S1R.
Peptides 9R and 9S1R target tumor heterogeneity
Tumors are heterogeneous in their composition [27] and
include non-cancer cells: cells of the stroma such as
macrophages, tumor-associated fibroblasts, and endothe-
lial cells. Tumor genetic heterogeneity is another dimen-
sion of their complexity that can promote resistance,
with cells from a single tumor having different genetic
makeup and therefore different responses to treatment.
Currently, genetic variation is the main reason for
chemo resistance in vivo [28]. We have tested the
Nullomer-derived peptides 9R and 9S1R against the gen-
etically heterogeneous NCI-60 panel representing nine
organs from 60 different donors. The peptides proved ef-
fective against a wide variety of cell and genetic types:
poorly differentiated and differentiated cancers, solid tu-
mors and cancers of the hematopoietic system, drug re-
sistant and drug sensitive cancer cells, hormone
dependent and hormone resistant cancers, cancer stem
cells, endothelial cells and macrophages [3], a carcino-
sarcoma cell line, actively dividing cancer cells and those
with very slow growth.
The ATP depletion effect of peptides 9R and 9S1R
The ATP depletion effect of peptide 9S1R is rapid, almost
as rapid as the anthrax lethal toxin [29], and much faster
than the effect of 100 mM of sodium azide [30]. Cancer
cell metabolism is often dependent on glycolysis for its
ATP (the “Warburg effect”). However, there is a large vari-
ation in the relative contributions of glycolysis and oxida-
tive phosphorylation (Kreb’s cycle, the respiratory chain
and the F0F1-ATP Synthase) in the ATP production of dif-
ferent cancer cells [31]. According to Zu et al., the ATP
produced by glycolysis can represent between 0.32and
64% of the cellular total [32]. Therefore, the ATP deple-
tion effect of the glycolysis inhibitor [3-bromo pyruvate
(3-BP)] or oligomycin (specific inhibitor of the proton
channel F0 subunit of the mitochondrial F0F1-ATPase)
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depends on the relative contribution of mitochondrial ver-
sus glycolytic ATP production [33]. In different cancer cell
lines, 3-BP can totally deplete cellular ATP [34] or have
no effect at all [35]. In the same vein, oligomycin has been
shown to deplete cellular ATP in the MCF7 cell line [36],
but not in MDA-MB-231 [36] or PC-3 cell lines [37].
For the NCI-60 panel, there is no literature concerning
the relative contribution of mitochondrial versus glycolytic
production in the total cellular ATP pool. According to
Evans et al. [33], the highly glycolytic cells have an overex-
pression of glucose transporter Glut-1 that confers a poor
prognosis for a wide variety of solid tumors. To deplete
the total ATP content of cell, it would be necessary to in-
hibit both glycolysis and oxidative phosphorylation.
Among the nine cancer cell lines that we tested for ATP
production, all proved sensitive for the peptide 9S1R ATP
depletion effect, while only four cell lines (U-251, EKVX,
COLO 205 and K-562) are sensitive to oligomycin [38].
Our data shows that the dramatic reduction in cellular
ATP seen within 3 h of 9S1R incubation is not always con-
cordant with cell death. How this depletion is achieved is
still unknown.
We also measured supernatant ATP in nine cancer cell
lines, and show that both 9R and 9SR1 deplete super-
natant ATP content in only COLO 205, DU-145 and K-
562. We hypothesize that the ATP found in the cellular
supernatant may have been secreted by the ectopic ex-
pression of F0F1-ATP Synthase, which is relocated to the
surface of tumor cells [9]. We note that there is no current
drug or chemical, with the exception of anthrax lethal
toxin, capable of shutting down all the ATP production in
cancer cells. Future work will be needed to exploit the
ATP depletion effects of peptides 9R and 9S1R.
At 25 μM concentration 9R and 9S1R are more lethal to
many cancer cell lines than to normal cell lines
We have looked at the vitality of all the NCI-60 cell lines
when exposed to 5 μM, 25 μM and 50 μM of each
Nullomer-derived peptide (“Additional file 1: Results S1”).
We note significant effects against 52 of the 60 cancer cell
lines with the incubation of 25 μM 9S1R. This 25 μM dose
has no significant effects against the 2 of the 4 normal cell
lines we tested: HUVEC (endothelium) and BJ (skin). On
a third normal cell line, FHC (intestinal), 25 μM 9S1R re-
sulted in a 74% SI, which is less of a lethal affect than seen
for many of the cancer lines tested. While 25 μM 9S1R re-
sulted in an SI of only 21% for RWPE-1 (normal prostate),
it should be noted that non-cancerous adult prostate cells
may respond quite differently than the early-passage cells
we screened in culture. It should also be noted that in our
earlier study using PCS normal prostate cells, we found
that the cancer line LnCap is more sensitive than normal
prostate cells [3] to the Nullomer drugs.
As noted in the results, Nullomer-derived 9R is gener-
ally safer for normal cells than 9S1R. At 25 μM, 9R has no
effect on HUVEC or BJ normal cell lines; and the effect
on the intestinal cell line (FHC) was below our sensitivity
threshold of 20% (90% remained viable). Of the four nor-
mal cells lines examined, RWPE-1 prostate cells showed
the greatest sensitivity to 9R, dropping just below our sen-
sitivity threshold of 20%, (the cells were 79% viable).
Conclusion
Current cancer therapy suffers from many limitations in-
cluding drug resistance and toxicity. We have produced
novel anti–cancer drugs based on the shortest peptide
sequences absent form natural proteins, Nullomers.
These pentamer (5-amino acid) sequences combined
with five R residues (for cell penetration) are effective
against 58 of the 60 cancer cell types in the NCI-60 can-
cer panel. While the mechanism (s) of their effects re-
quire further research, the peptides clearly affect cellular
ATP production, have differential effects on various can-
cer cell types, and are more toxic to many cancers than
most normal cell types tested.
No current anti-cancer drug, even those targeting
DNA replication or the mitotic apparatus, is effective
against cancers derived from all nine organs represented
in the NCI-60 panel. However, Nullomer-derived pep-
tides 9S1R and 9R are active against 95 and 81.6%, re-
spectively, of the NCI-60 cancer cell lines. Both peptides
are active against dividing and quiescent, drug resistant
and drug sensitive, hormone sensitive and hormone re-
sistant, differentiated and non-differentiated, metastatic
and non-metastatic cancer cell lines. In addition, both
peptides are active against cancer stem cell lines. There-
fore, peptides 9S1R and 9R address the problem of
tumor heterogeneity–a fundamental challenge in cancer
treatment. We propose the hypotheses that this broad
activity spectrum is due to the fact that both peptides
target “cells of origin of cancer” [14], these are cells car-
rying common marker (s) of cancers derived from many
organs. Both peptides, especially peptide 9S1R, kill can-
cer cells by rapidly depleting ATP content. Future stud-
ies will evaluate the Nullomer-derived peptides’ effects
on invasion ability and metastasis in animal models.
Studies that combine the Nullomer-derived peptides
with other drugs will examine if depriving ATP-
dependent pumps of power, will decrease MDR caused
by the efflux of anti-cancer drugs.
Additional files
Additional file 1: Results 1. Effect of 50 μM, 25 μM and 5 μM Nullomer
peptides on cancer cell line growth. Cells (3000-5000 cells/well) were
seeded in 96-well plates. After 24 h incubation, peptides 9R, 9S1R and
124R were added to the wells with untreated cells as control. After 48 h
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exposure to the peptides, cell viability was quantified by the addition of
10 μl of cell counting kit (CCK-8, Dojindo Japan) to each well, which was
then incubated for 4 h at 37 °C in a 5% CO2 incubator. After incubation,
plates were monitored by a microplate reader (BioTek) at an absorbance
of 450 nm. Controls: untreated cells and empty wells. Each panel is a
representative of three experiments. (A) Kidney, (B) Prostate, (C) Ovarian,
(D) Leukemia Lymphoma, (E) Colon, (F) Melanoma, (G) Breast, (H) CNS,
and (I) Lung cancer cell lines. Results are as mean ± SE (standard error) of
threedifferent experiments. NS, not significant. *p<0.05,**p<0.01,***p< 0.001.
(PDF 534 kb)
Additional file 2: Table 1. Survival index (SI) and response categories
of the NCI-60 panel. A: SI of NCI-60 cancer cell lines after 48 h with
50 μM peptides 9R, 9S1R and 124R; B: % of cell lines sensitive and resistant
to peptides 9R, 9S1R and 124R; C: Peptides 9R, 9S1R and 124R response
categories; D: SI and response categories for normal cell lines treated with
9R, 9S1R and 124R. Sensitive lines experience at least 20% decrease in the
number of living cells after 48 h treatment. (XLSX 14 kb)
Additional file 3: Table 2. Spectrum activity of peptides 9R, 9S1R and
124R and current anticancer drugs (reference [9]). Comparison of Nullomer
derived peptides (9R and 9S1R) sensitivity with current anticancer drugs
approved by the FDA. (XLSX 13 kb)
Additional file 4:Results 2. Effect of 50 μM, 25 μM and 5 μM Nullomer
peptides on normal cell growth. Cells (3000-5000 cells/well) were seeded
in 96-well plates. After 24 h incubation, peptides 9R, 9S1R and 124R were
added to the wells, with untreated cells as control. After 48 h exposure
to the peptides, cell viability was quantified by the addition of 10 μl of
cell counting kit (CCK-8, Dojindo Japan) to each which was then incubated
for 4 h at 37 °C in a 5% CO2 incubator. After the incubation, the plates were
monitored by a microplate reader (BioTek) at an absorbance of 450 nm. (A)
Endothelial cell line, (B) Skin fibroblast, (C) Prostate cell line, (D) Intestinal cell
line. Results are as mean ± SE (standard error) of three different experiments.
NS, not significant. *p<0.05,**p <0.01, ***p<0.001. (PDF 276 kb)
Additional file 5:Table 3 ATP depletion of cancer and normal cell lines
after treatment with 9R, 9S1R and 124R. ATP content: expressed as % of
control. Three-hour incubations with 50uM peptide. (XLSX 9 kb)
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